In addition, the follow-up results exhibited that glioma patients with higher DRD2 expression showed poorer prognosis than those with lower DRD2 expression, while this was not the case for β-catenin (Fig. 5I,5J). This evidence concerns the gene DRD2 and central nervous system cancer.